Interventional Psychiatry Market Report: TMS vs. Spravato
Medicare TMS (90867–90869) and Spravato (Part B G2082/G2083, Part D, Medicaid) · 2022–2024
Side-by-side adoption of the two leading treatment-resistant depression modalities from completed CMS imports: providers, services, payments, states and multi-modality clinicians, with programs never summed.
Built for Interventional psychiatry clinics, neurostimulation and esketamine field teams, and behavioral-health M&A advisors.
What's inside the full paper
- Executive summary
- TMS: Medicare providers, services and payments by year
- TMS by code
- Spravato by program and year
- State adoption comparison (2024 TMS vs. 2024 Spravato Part D)
- TMS clinician specialties (2024)
- Methods and limits
Free preview
Executive summary
Prepared 2026-11-20 from completed CMS imports. In 2024, 391 Medicare clinicians billed TMS (90867–90869); 1,338 distinct NPIs appear in 2024 Spravato records across Medicare Part B, Part D and Medicaid.
TMS Medicare payments moved from $22,166,329 (2022) to $35,443,306 (2024). 95 clinicians appear in both the latest TMS and Spravato cohorts — the multi-modality interventional practices most likely to expand.
Programs are shown side by side and never summed: Part B pays the in-office administration and monitoring, Part D pays the drug, and Medicaid uses different reporting.
TMS: Medicare providers, services and payments by year
Payments are services × CMS average Medicare payment per rendering NPI, code and place of service.
| Year | Clinicians | Services | Medicare paid |
|---|---|---|---|
| 2022 | 310 | 157,762 | $22,166,329 |
| 2023 | 319 | 168,342 | $23,393,041 |
| 2024 | 391 | 239,355 | $35,443,306 |
TMS by code
90867 initial mapping, 90868 subsequent delivery, 90869 re-mapping.
| Year | Code | Clinicians | Services | Medicare paid |
|---|---|---|---|---|
| 2022 | 90867 | 159 | 3,684 | $739,896 |
| 2022 | 90868 | 309 | 152,069 | $21,015,926 |
| 2022 | 90869 | 61 | 2,009 | $410,507 |
6 more rows in the full paper
Statistical results are review leads, not findings of fraud. See our sources.
